WO2023094662 - TREATMENT OF RHABDOMYOSARCOMA
National phase entry:
Publication Number
WO/2023/094662
Publication Date
01.06.2023
International Application No.
PCT/EP2022/083503
International Filing Date
28.11.2022
Title **
[English]
TREATMENT OF RHABDOMYOSARCOMA
[French]
TRAITEMENT DU RHABDOMYOSARCOME
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
Inventors
POZZO, Enrico
SAMPAOLESI, Maurilio
Priority Data
21210802.1
26.11.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2189 | |
| EPO | Filing, Examination, Granting | 9193 | |
| Japan | Filing, Examination, Granting | 2201 | |
| South Korea | Filing, Examination, Granting | 2122 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
22,245
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to the use of Mir-340 and mir-449a the treatment or prevention soft tissue sarcomas, such as rhabdomyosarcoma.[French]
L'invention concerne l'utilisation de mir-340 et mir-449a pour traiter ou prévenir des sarcomes de tissus mous, tels que le rhabdomyosarcome.